<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36405622</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Fecal microbiota transplantation in irritable bowel syndrome: A meta-analysis of randomized controlled trials.</ArticleTitle><Pagination><StartPage>1039284</StartPage><MedlinePgn>1039284</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1039284</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2022.1039284</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Fecal microbiota transplantation (FMT) has been proposed as a potential treatment for irritable bowel syndrome (IBS); however, the consensus regarding its efficacy and safety is limited.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">We performed a systematic search of the literature using PubMed, EMBASE, Ovid MEDLINE, and Cochrane. Meta-analyses were conducted in relative risk (RR) or standard mean difference (SMD) using 95% confidence intervals (CI). Cochrane risk-of-bias 2 tool (RoB2) was employed to evaluate the study quality.</AbstractText><AbstractText Label="RESULT" NlmCategory="UNASSIGNED">Of 2,589 potential records, 7 studies with 9 cohorts involving 505 participants were included. Meta-analyses showed no significant difference in the short-term (12 weeks) and long-term (12 months) global improvement of IBS symptoms of FMT vs. placebo (RR 0.63, 95% CI 0.39-1.00 and RR 0.88, 95% CI 0.53-1.45, respectively). There were statistically significant differences of short-term IBS-SSS improvement (SMD -0.58, 95% CI -1.09 to -0.88) and short-term IBS-QoL improvement (SMD 0.67, 95% CI 0.43-0.91). Eight from 9 studies (88.9%) had a low risk of bias. The subgroup analysis revealed the short-term global symptoms improvement in studies with low-risk of bias (RR 0.53, 95% CI 0.35-0.81), studies with well-defined donors (RR 0.31, 95% CI 0.14-0.72), and studies with FMT using colonoscopy (RR 0.66, 95% CI 0.47-0.92). Major FMT adverse events are transient and rapidly self-limiting.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">FMT significantly improved IBS-SSS and IBS-QoL in the short-term period in IBS patients. However, global symptom improvement showed no significance. Well-defined donors and appropriate fecal administration routes appear to be important factors for the successful outcomes of FMT in IBS.</AbstractText><AbstractText Label="SYSTEMATIC REVIEW REGISTRATION" NlmCategory="UNASSIGNED">[www.crd.york.ac.uk/prospero], identifier [CRD42021246101].</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Samuthpongtorn, Kantagowit, Pittayanon, Patcharatrakul and Gonlachanvit.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Samuthpongtorn</LastName><ForeName>Chatpol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kantagowit</LastName><ForeName>Piyawat</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pittayanon</LastName><ForeName>Rapat</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patcharatrakul</LastName><ForeName>Tanisa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Neurogastroenterology and Motility, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonlachanvit</LastName><ForeName>Sutep</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Neurogastroenterology and Motility, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dysbiosis</Keyword><Keyword MajorTopicYN="N">fecal microbiota transplantation</Keyword><Keyword MajorTopicYN="N">gastrointestinal diseases</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>21</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36405622</ArticleId><ArticleId IdType="pmc">PMC9669599</ArticleId><ArticleId IdType="doi">10.3389/fmed.2022.1039284</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mearin F, Lacy B, Chang L, Chey W, Lembo A, Simren M, et al. 
Bowel disorders.
<i>Gastroenterology</i>. (2016) 150:1393&#x2013;407.e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">27144627</ArticleId></ArticleIdList></Reference><Reference><Citation>Owyang C. Irritable bowel syndrome.
20th ed. In: Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J.
editors.
<i>Harrison&#x2019;s principles of internal medicine.</i>
New York, NY: McGraw Hill;  (2018).</Citation></Reference><Reference><Citation>Sperber A, Dumitrascu D, Fukudo S, Gerson C, Ghoshal U, Gwee K, et al. 
The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: A Rome Foundation working team literature review.
<i>Gut.</i> (2017) 66:1075&#x2013;82. 10.1136/gutjnl-2015-311240
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311240</ArticleId><ArticleId IdType="pubmed">26818616</ArticleId></ArticleIdList></Reference><Reference><Citation>Gralnek I, Hays R, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life.
<i>Gastroenterology.</i> (2000) 119:654&#x2013;60. 10.1053/gast.2000.16484
</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/gast.2000.16484</ArticleId><ArticleId IdType="pubmed">10982758</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel B. The burden of IBS: Looking at metrics.
<i>Curr Gastroenterol Rep.</i> (2009) 11:265&#x2013;9. 10.1007/s11894-009-0039-x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11894-009-0039-x</ArticleId><ArticleId IdType="pubmed">19615301</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber A, Bangdiwala S, Drossman D, Ghoshal U, Simren M, Tack J, et al. 
Worldwide prevalence and burden of functional gastrointestinal disorders, results of rome foundation global study.
<i>Gastroenterology.</i> (2021) 160:99&#x2013;114e3. 10.1053/j.gastro.2020.04.014
</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.04.014</ArticleId><ArticleId IdType="pubmed">32294476</ArticleId></ArticleIdList></Reference><Reference><Citation>Chey W, Kurlander J, Eswaran S. Irritable bowel syndrome: A clinical review.
<i>JAMA.</i> (2015) 313:949&#x2013;58. 10.1001/jama.2015.0954
</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.0954</ArticleId><ArticleId IdType="pubmed">25734736</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll I, Ringel-Kulka T, Keku T, Chang Y, Packey C, Sartor R, et al. 
Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome.
<i>Am J Physiol Gastrointest Liver Physiol.</i> (2011) 301:G799&#x2013;807. 10.1152/ajpgi.00154.2011
</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00154.2011</ArticleId><ArticleId IdType="pmc">PMC3220325</ArticleId><ArticleId IdType="pubmed">21737778</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll I, Ringel-Kulka T, Siddle J, Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome.
<i>Neurogastroenterol Motil.</i> (2012) 24:521&#x2013;30,e248. 10.1111/j.1365-2982.2012.01891.x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2012.01891.x</ArticleId><ArticleId IdType="pmc">PMC3975596</ArticleId><ArticleId IdType="pubmed">22339879</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattarai Y, Muniz Pedrogo D, Kashyap P. Irritable bowel syndrome: A gut microbiota-related disorder?
<i>Am J Physiol Gastrointest Liver Physiol.</i> (2017) 312:G52&#x2013;62. 10.1152/ajpgi.00338.2016
</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00338.2016</ArticleId><ArticleId IdType="pmc">PMC5283907</ArticleId><ArticleId IdType="pubmed">27881403</ArticleId></ArticleIdList></Reference><Reference><Citation>Tap J, Derrien M, T&#xf6;rnblom H, Brazeilles R, Cools-Portier S, Dor&#xe9; J, et al. 
Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome.
<i>Gastroenterology.</i> (2017) 152:111&#x2013;123e8. 10.1053/j.gastro.2016.09.049
</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.09.049</ArticleId><ArticleId IdType="pubmed">27725146</ArticleId></ArticleIdList></Reference><Reference><Citation>Menees S, Chey W. The gut microbiome and irritable bowel syndrome.
<i>F1000Res.</i> (2018) 7:F1000FacultyRev&#x2013;1029. 10.12688/f1000research.14592.1
</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.14592.1</ArticleId><ArticleId IdType="pmc">PMC6039952</ArticleId><ArticleId IdType="pubmed">30026921</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittayanon R, Lau JT, Yuan Y, Leontiadis G, I, Tse F, Surette M, et al. 
Gut Microbiota in patients with irritable bowel syndrome&#x2013;a systematic review.
<i>Gastroenterology.</i> (2019) 157:97&#x2013;108. 10.1053/j.gastro.2019.03.049
</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.03.049</ArticleId><ArticleId IdType="pubmed">30940523</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A, Harris L, Lacy B, Quigley E, Moayyedi P. Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome.
<i>Aliment Pharmacol Ther.</i> (2018) 48:1044&#x2013;60. 10.1111/apt.15001
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Dionne J, Ford A, Yuan Y, Chey W, Lacy B, Saito Y, et al. 
A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAPs diet in treating symptoms of irritable bowel syndrome.
<i>Am J Gastroenterol.</i> (2018) 113:1290&#x2013;300. 10.1038/s41395-018-0195-4
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41395-018-0195-4</ArticleId><ArticleId IdType="pubmed">30046155</ArticleId></ArticleIdList></Reference><Reference><Citation>Panebianco C, Andriulli A, Pazienza V. Pharmacomicrobiomics: Exploiting the drug-microbiota interactions in anticancer therapies.
<i>Microbiome.</i> (2018) 6:92. 10.1186/s40168-018-0483-7
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-018-0483-7</ArticleId><ArticleId IdType="pmc">PMC5964925</ArticleId><ArticleId IdType="pubmed">29789015</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M, Hatlebakk J, Gilja O, Br&#xe5;then Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study.
<i>Gut.</i> (2020) 69:859&#x2013;67. 10.1136/gutjnl-2019-319630
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2019-319630</ArticleId><ArticleId IdType="pmc">PMC7229896</ArticleId><ArticleId IdType="pubmed">31852769</ArticleId></ArticleIdList></Reference><Reference><Citation>Holvoet T, Joossens M, V&#xe1;zquez-Castellanos J, Christiaens E, Heyerick L, Boelens J. Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: Short- and long-term results from a placebo-controlled randomized trial.
<i>Gastroenterology.</i> (2021) 160:145&#x2013;157e8. 10.1053/j.gastro.2020.07.013
</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.07.013</ArticleId><ArticleId IdType="pubmed">32681922</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnsen P, Hilp&#xfc;sch F, Cavanagh J, Leikanger I, Kolstad C, Valle P, et al. 
Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: A double-blind, randomised, placebo-controlled, parallel-group, single-centre trial.
<i>Lancet Gastroenterol Hepatol.</i> (2018) 3:17&#x2013;24. 10.1016/S2468-1253(17)30338-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(17)30338-2</ArticleId><ArticleId IdType="pubmed">29100842</ArticleId></ArticleIdList></Reference><Reference><Citation>Halkj&#xe6;r S, Christensen A, Lo B, Browne P, G&#xfc;nther S, Hansen L, et al. 
Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: Results from a randomised, double-blind placebo-controlled study.
<i>Gut.</i> (2018) 67:2107&#x2013;15. 10.1136/gutjnl-2018-316434
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2018-316434</ArticleId><ArticleId IdType="pubmed">29980607</ArticleId></ArticleIdList></Reference><Reference><Citation>Aroniadis O, Brandt L, Oneto C, Feuerstadt P, Sherman A, Wolkoff A, et al. 
Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: A double-blind, randomised, placebo-controlled trial.
<i>Lancet Gastroenterol Hepatol.</i> (2019) 4:675&#x2013;85. 10.1016/S2468-1253(19)30198-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(19)30198-0</ArticleId><ArticleId IdType="pubmed">31326345</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M, Patcharatrakul T, Gonlachanvit S. Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21(st) century.
<i>World J Gastroenterol.</i> (2021) 27:2921&#x2013;43. 10.3748/wjg.v27.i22.2921
</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v27.i22.2921</ArticleId><ArticleId IdType="pmc">PMC8192290</ArticleId><ArticleId IdType="pubmed">34168399</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H-J, Zhang X-J, Zhang N-N, Yan B, Xu K-K, Peng L-H, et al. 
Fecal microbiota transplantation for patients with irritable bowel syndrome: A meta-analysis of randomized controlled trials.
<i>Front Nutr.</i> (2022) 9:890357. 10.3389/fnut.2022.890357
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2022.890357</ArticleId><ArticleId IdType="pmc">PMC9202577</ArticleId><ArticleId IdType="pubmed">35719141</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Lv L, Wang C. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: A meta-analysis of randomized controlled trials.
<i>Front Cell Infect Microbiol.</i> (2022) 12:827395. 10.3389/fcimb.2022.827395
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.827395</ArticleId><ArticleId IdType="pmc">PMC8919053</ArticleId><ArticleId IdType="pubmed">35295757</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. 
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation.
<i>BMJ.</i> (2015) 350:g7647. 10.1136/bmj.g7647
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g7647</ArticleId><ArticleId IdType="pubmed">25555855</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Zanten SV, Talley N, Bytzer P, Klein K, Whorwell P, Zinsmeister A. Design of treatment trials for functional gastrointestinal disorders.
<i>Gut.</i> (1999) 45:II69&#x2013;77. 10.1136/gut.45.2008.ii69
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.45.2008.ii69</ArticleId><ArticleId IdType="pmc">PMC1766689</ArticleId><ArticleId IdType="pubmed">10457048</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvine EJ, Tack J, Crowell MD, Gwee KA, Ke M, Schmulson MJ, et al. 
Design of treatment trials for functional gastrointestinal disorders.
<i>Gastroenterology.</i> (2016) 150:1469&#x2013;1480e1. 10.1053/j.gastro.2016.02.010
</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.010</ArticleId><ArticleId IdType="pubmed">27147123</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis.
<i>Stat Med.</i> (2002) 21:1539&#x2013;58. 10.1002/sim.1186
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.1186</ArticleId><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KO, Gluck M. Fecal microbiota transplantation: An update on clinical practice.
<i>Clin Endosc.</i> (2019) 52:137&#x2013;43. 10.5946/ce.2019.009
</Citation><ArticleIdList><ArticleId IdType="doi">10.5946/ce.2019.009</ArticleId><ArticleId IdType="pmc">PMC6453848</ArticleId><ArticleId IdType="pubmed">30909689</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakken J, Borody T, Brandt L, Brill J, Demarco D, Franzos M, et al. 
Treating clostridium difficile infection with fecal microbiota transplantation.
<i>Clin Gastroenterol Hepatol.</i> (2011) 9:1044&#x2013;9. 10.1016/j.cgh.2011.08.014
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2011.08.014</ArticleId><ArticleId IdType="pmc">PMC3223289</ArticleId><ArticleId IdType="pubmed">21871249</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt L. American journal of gastroenterology lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. Difficile infection.
<i>Am J Gastroenterol.</i> (2013) 108:177&#x2013;85. 10.1038/ajg.2012.450
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2012.450</ArticleId><ArticleId IdType="pubmed">23318479</ArticleId></ArticleIdList></Reference><Reference><Citation>Mccune V, Struthers J, Hawkey P. Faecal transplantation for the treatment of Clostridium difficile infection: A review.
<i>Int J Antimicrob Agents.</i> (2014) 43:201&#x2013;6. 10.1016/j.ijantimicag.2013.10.009
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2013.10.009</ArticleId><ArticleId IdType="pubmed">24636428</ArticleId></ArticleIdList></Reference><Reference><Citation>Cammarota G, Ianiro G, Tilg H, Rajili&#x107;-Stojanovi&#x107; M, Kump P, Satokari R, et al. 
European consensus conference on faecal microbiota transplantation in clinical practice.
<i>Gut.</i> (2017) 66:569&#x2013;80. 10.1136/gutjnl-2016-313017
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2016-313017</ArticleId><ArticleId IdType="pmc">PMC5529972</ArticleId><ArticleId IdType="pubmed">28087657</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullish B, Quraishi M, Segal J, Mccune V, Baxter M, Marsden G, et al. 
The use of faecal microbiota transplant as treatment for recurrent or refractory clostridium difficile infection and other potential indications: Joint British society of gastroenterology (BSG) and healthcare infection society (HIS) guidelines.
<i>Gut.</i> (2018) 67:1920&#x2013;41. 10.1136/gutjnl-2018-316818
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2018-316818</ArticleId><ArticleId IdType="pubmed">30154172</ArticleId></ArticleIdList></Reference><Reference><Citation>Cammarota G, Ianiro G, Kelly C, Mullish B, Allegretti J, Kassam Z, et al. 
International consensus conference on stool banking for faecal microbiota transplantation in clinical practice.
<i>Gut.</i> (2019) 68:2111&#x2013;21. 10.1136/gutjnl-2019-319548
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2019-319548</ArticleId><ArticleId IdType="pmc">PMC6872442</ArticleId><ArticleId IdType="pubmed">31563878</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng S, Kamm M, Yeoh Y, Chan P, Zuo T, Tang W, et al. 
Scientific frontiers in faecal microbiota transplantation: Joint document of asia-pacific association of gastroenterology (APAGE) and asia-pacific society for digestive endoscopy (APSDE).
<i>Gut.</i> (2020) 69:83&#x2013;91. 10.1136/gutjnl-2019-319407
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2019-319407</ArticleId><ArticleId IdType="pmc">PMC6943253</ArticleId><ArticleId IdType="pubmed">31611298</ArticleId></ArticleIdList></Reference><Reference><Citation>Haifer C, Kelly C, Paramsothy S, Andresen D, Papanicolas L, Mckew G, et al. 
Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice.
<i>Gut.</i> (2020) 69:801&#x2013;10. 10.1136/gutjnl-2019-320260
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2019-320260</ArticleId><ArticleId IdType="pubmed">32047093</ArticleId></ArticleIdList></Reference><Reference><Citation>Holster S, Lindqvist CM, Repsilber D, Salonen A, de Vos WM, K&#xf6;nig J, et al. 
The effect of allogenic versus autologous fecal microbiota transfer on symptoms, visceral perception and fecal and mucosal microbiota in irritable bowel syndrome: A randomized controlled study.
<i>Clin Transl Gastroenterol.</i> (2019) 10:e00034. 10.14309/ctg.0000000000000034
</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ctg.0000000000000034</ArticleId><ArticleId IdType="pmc">PMC6602784</ArticleId><ArticleId IdType="pubmed">31009405</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahtinen P, Jalanka J, Hartikainen A, Mattila E, Hillil&#xe4; M, Punkkinen J, et al. 
Randomised clinical trial: Faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome.
<i>Aliment Pharmacol Ther.</i> (2020) 51:1321&#x2013;31. 10.1111/apt.15740
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15740</ArticleId><ArticleId IdType="pubmed">32343000</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. 
<i>Cochrane handbook for systematic reviews of interventions version 6.2 [Online].</i>
Cochrane;  (2021). Available online at: www.training.cochrane.org/handbook
(accessed July 7, 2022).</Citation></Reference><Reference><Citation>Mohammad S, Di Lorenzo C, Youssef NN, Miranda A, Nurko S, Hyman P, et al. 
Assessment of abdominal pain through global outcomes and recent FDA recommendations in children: Are we ready for change?
<i>J Pediatr Gastroenterol Nutr.</i> (2014) 58:46&#x2013;50. 10.1097/MPG.0b013e3182a20764
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0b013e3182a20764</ArticleId><ArticleId IdType="pmc">PMC4641447</ArticleId><ArticleId IdType="pubmed">23857339</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalanka J, Mattila E, Jouhten H, Hartman J, De Vos WM, Arkkila P, et al. 
Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection.
<i>BMC Med.</i> (2016) 14:155. 10.1186/s12916-016-0698-z
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-016-0698-z</ArticleId><ArticleId IdType="pmc">PMC5057499</ArticleId><ArticleId IdType="pubmed">27724956</ArticleId></ArticleIdList></Reference><Reference><Citation>Li SS, Zhu A, Benes V, Costea P, I, Hercog R, Hildebrand F, et al. 
Durable coexistence of donor and recipient strains after fecal microbiota transplantation.
<i>Science.</i> (2016) 352:586&#x2013;9. 10.1126/science.aad8852
</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad8852</ArticleId><ArticleId IdType="pubmed">27126044</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J, Lin Z, Tian H, Yang B, Zhao D, Ye C, et al. 
Long-term follow-up results of fecal microbiota transplantation for irritable bowel syndrome: A single-center, retrospective study.
<i>Front Med.</i> (2021) 8:710452. 10.3389/fmed.2021.710452
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.710452</ArticleId><ArticleId IdType="pmc">PMC8362996</ArticleId><ArticleId IdType="pubmed">34395484</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M, Hausken T, Hatlebakk JG. Increasing the dose and/or repeating faecal microbiota transplantation (FMT) increases the response in patients with irritable bowel syndrome (IBS).
<i>Nutrients.</i> (2019) 11:1415. 10.3390/nu11061415
</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11061415</ArticleId><ArticleId IdType="pmc">PMC6628324</ArticleId><ArticleId IdType="pubmed">31238507</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C, Grunert PC, Stallmach A. An update for pharmacologists on new treatment options for inflammatory bowel disease: The clinicians&#x2019; perspective.
<i>Front Pharmacol.</i> (2021) 12:655054. 10.3389/fphar.2021.655054
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.655054</ArticleId><ArticleId IdType="pmc">PMC8072211</ArticleId><ArticleId IdType="pubmed">33912062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooijevaar R, Terveer E, Verspaget H, Kuijper E, Keller J. Clinical application and potential of fecal microbiota transplantation.
<i>Annu Rev Med.</i> (2019) 70:335&#x2013;51. 10.1146/annurev-med-111717-122956
</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-111717-122956</ArticleId><ArticleId IdType="pubmed">30403550</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull M, Plummer N. Part 2: Treatments for chronic gastrointestinal disease and gut dysbiosis.
<i>Integr Med.</i> (2015) 14:25&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4566455</ArticleId><ArticleId IdType="pubmed">26770128</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S, Xie S, Lv D, Wang P, He H, Zhang T, et al. 
Alteration of the gut microbiota in Chinese population with chronic kidney disease.
<i>Sci Rep.</i> (2017) 7:2870. 10.1038/s41598-017-02989-2
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-02989-2</ArticleId><ArticleId IdType="pmc">PMC5460291</ArticleId><ArticleId IdType="pubmed">28588309</ArticleId></ArticleIdList></Reference><Reference><Citation>Rychlik I. Chapter 10 &#x2013; Monitoring microbiota in chickens and pigs. In: FOSTER N, KYRIAZAKIS I, BARROW P.
editors.
<i>Advancements and technologies in pig and poultry bacterial disease control.</i>
Cambridge, MA: Academic Press;  (2021). 10.1016/B978-0-12-818030-3.00003-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-818030-3.00003-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Hati S, Patel M, Mishra BK, Das S. Short-chain fatty acid and vitamin production potentials of <i>Lactobacillus</i> isolated from fermented foods of Khasi Tribes, Meghalaya, India.
<i>Ann Microbiol.</i> (2019) 69:1191&#x2013;9. 10.1007/s13213-019-01500-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13213-019-01500-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajic D, Niemann A, Hillmer A, Mejias-Luque R, Bluemel S, Docampo M, et al. 
Gut microbiota-derived propionate regulates the expression of Reg3 mucosal lectins and ameliorates experimental colitis in mice.
<i>J Crohns Colitis.</i> (2020) 14:1462&#x2013;72. 10.1093/ecco-jcc/jjaa065
</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjaa065</ArticleId><ArticleId IdType="pmc">PMC8921751</ArticleId><ArticleId IdType="pubmed">32227170</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuillermin PJ, O&#x2019;HELY M, Collier F, Allen KJ, Tang MLK, Harrison LC, et al. 
Maternal carriage of prevotella during pregnancy associates with protection against food allergy in the offspring.
<i>Nat Commun.</i> (2020) 11:1452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7093478</ArticleId><ArticleId IdType="pubmed">32210229</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, He X, Sheng Y, Yang C, Xu J, Zheng S, et al. 
Allicin-induced host-gut microbe interactions improves energy homeostasis.
<i>FASEB J.</i> (2020) 34:10682&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">32619085</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Siles M, Duncan S, Garcia-Gil L, Martinez-Medina M. Faecalibacterium prausnitzii: From microbiology to diagnostics and prognostics.
<i>ISME J.</i> (2017) 11:841&#x2013;52. 10.1038/ismej.2016.176
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ismej.2016.176</ArticleId><ArticleId IdType="pmc">PMC5364359</ArticleId><ArticleId IdType="pubmed">28045459</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D, Chen V, Steiner C, Berinstein J, Eswaran S, Waljee A, et al. 
Efficacy of fecal microbiota transplantation in irritable bowel syndrome: A systematic review and meta-analysis.
<i>Am J Gastroenterol.</i> (2019) 114:1043&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7257434</ArticleId><ArticleId IdType="pubmed">30908299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramai D, Zakhia K, Fields PJ, Ofosu A, Patel G, Shahnazarian V, et al. 
Fecal microbiota transplantation (FMT) with colonoscopy is superior to enema and nasogastric tube while comparable to capsule for the treatment of recurrent clostridioides difficile infection: A systematic review and meta-analysis.
<i>Dig Dis Sci.</i> (2021) 66:369&#x2013;80. 10.1007/s10620-020-06185-7
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-020-06185-7</ArticleId><ArticleId IdType="pubmed">32166622</ArticleId></ArticleIdList></Reference><Reference><Citation>Colman R, Rubin D. Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis.
<i>J Crohns Colitis.</i> (2014) 8:1569&#x2013;81. 10.1016/j.crohns.2014.08.006
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crohns.2014.08.006</ArticleId><ArticleId IdType="pmc">PMC4296742</ArticleId><ArticleId IdType="pubmed">25223604</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati M, Singh SK, Corrie L, Kaur IP, Chandwani L. Delivery routes for faecal microbiota transplants: Available, anticipated and aspired.
<i>Pharmacol Res.</i> (2020) 159:104954. 10.1016/j.phrs.2020.104954
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.104954</ArticleId><ArticleId IdType="pubmed">32492490</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, et al. 
Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent clostridium difficile infection: A randomized clinical trial.
<i>JAMA.</i> (2016) 315:142&#x2013;9. 10.1001/jama.2015.18098
</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.18098</ArticleId><ArticleId IdType="pubmed">26757463</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KO, Schwartz MA, Lin OST, Chiorean MV, Gluck M. Reducing cost and complexity of fecal microbiota transplantation using universal donors for recurrent clostridium difficile infection.
<i>Adv Ther.</i> (2019) 36:2052&#x2013;61. 10.1007/s12325-019-00974-x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-019-00974-x</ArticleId><ArticleId IdType="pmc">PMC6822862</ArticleId><ArticleId IdType="pubmed">31154629</ArticleId></ArticleIdList></Reference><Reference><Citation>Edelstein C, Daw JR, Kassam Z. Seeking safe stool: Canada needs a universal donor model.
<i>CMAJ Can Med Assoc J.</i> (2016) 188:E431&#x2013;2. 10.1503/cmaj.150672
</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.150672</ArticleId><ArticleId IdType="pmc">PMC5135517</ArticleId><ArticleId IdType="pubmed">26696614</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne J, Sutton A, Ioannidis J, Terrin N, Jones D, Lau J, et al. 
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.
<i>BMJ.</i> (2011) 343:d4002. 10.1136/bmj.d4002
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d4002</ArticleId><ArticleId IdType="pubmed">21784880</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>